Provention Bio is on track to complete submission of a BLA for its T1D drug Teplizumab by the end of 2020.
This will revolutionise treatment of at-risk T1D patients. The company received the Breakthrough Therapy Designation from FDA.
The company is significantly undervalued on this indication alone — but has enormous potential in other indications.
Comments are closed.